PE
GLUE icon

Point72 Europe’s Monte Rosa Therapeutics GLUE Stock Holding History

Point72 Europe’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$4.38K Buy
+591
New +$3.13K ﹤0.01% 610

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Point72 Europe's GLUE Position: Q3 2025 in Review

Point72 Europe opened a new position in Monte Rosa Therapeutics (GLUE) in Q3 2025: 591 shares worth $4.38K. The stake represents ﹤0.01% of the portfolio and ranks #610 among its holdings.

129 funds tracked by Wall St. Rank hold GLUE as of Q3 2025.

  • Point72 Europe held 591 shares of Monte Rosa Therapeutics worth $4.38K as of Q3 2025.
  • Monte Rosa Therapeutics was a new Point72 Europe position in Q3 2025.
  • Monte Rosa Therapeutics made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #610 holding.
  • 129 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.